Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment

Fig. 3

Effect of cisplatin and ACY-1083 on α-tubulin acetylation and HDAC6 expression. Mice were treated with two 5-day cycles of cisplatin or PBS, followed by 11 daily administrations of ACY-1083. Brains were collected 3 h after the last injection of ACY-1083. a Acetylated α-tubulin (n = 4; two-way ANOVA with Tukey’s post-hoc analysis: F (1, 12) = 6.765; PBS vs. Cisplatin, p = 0.0408; Cisplatin vs. Cisplatin + ACY-1083, p = 0.0170) and (b) HDAC6 expression (n = 4; two-way ANOVA, F (1, 12) = 0.7129, p = 0.4150) levels were assessed by Western blot analysis. Results are expressed as mean ± SEM; *P < 0.05

Back to article page